Developmental Funds

发展基金

• 批准号: 10589916
• 负责人: GUSTAVO Walter LEONE
• 金额: $ 58.11万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10589916
• 关键词: Area; Award; Basic Science; Biochemistry; Biological Markers; Cancer Biology; Cancer Center; Cancer Center Support Grant; Catchment Area; Cell Separation; Cells; Charge; Clinical; Clinical Investigator; Clinical Research; Cytometry; Development; Doctor of Philosophy; Effectiveness; Endowment; Extramural Activities; Faculty; Faculty Recruitment; Flow Cytometry; Funding; Grant; Growth; Immunology; Institution; Investments; Link; Malignant Neoplasms; Medical; Microbiology; Molecular; Molecular Biology; Pennsylvania; Pharmacology; Physicians; Play; Proteomics; Research; Research Personnel; Resource Sharing; Role; Science; Scientist; Sorting; Source; South Carolina; Strategic Planning; Therapeutic; Time; Translational Research; Universities; anticancer research; dimensional analysis; high dimensionality; high reward; high risk; innovation; interdisciplinary collaboration; investigator-initiated trial; lipidomics; meetings; multidisciplinary; pre-clinical; professor; programs; recruit; technology platform; tumor immunology

DEVELOPMENTAL FUNDS: SUMMARY The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) utilizes the Cancer Center Support Grant (CCSG) developmental funds to fuel its strategic plans for advancement of junior investigators, team science, translational and clinical research, and support of strategic faculty recruitments. During the current project period a total of $633,635 of CCSG developmental funds were distributed for pilot research funding in support of nine projects. Including the CCSG funds, HCC invested a total of $2.7 million in pilot research funds awarded between 2013-2018, which can be directly linked to the successful award of $26 million in extramural, multi-year grant funding. This is a nearly 10-fold yield from the investment of CCSG dollars. In addition, CCSG developmental funds supported the recruitment of three new faculty recruits supporting the expansion of scientific expertise in the Cancer Biology (CB), Developmental Cancer Therapeutics (DCT), and Cancer Immunology (CI) Programs. J. Alan Diehl, PhD and Professor of Biochemistry & Molecular Biology holds the SmartState Endowed Professor of Lipidomics and Pathobiology Chair. Diehl was recruited to MUSC in 2014 from the University of Pennsylvania to serve as the Associate Director of Basic Science. His research is currently funded by an NCI R01 and three NCI P01s. Anand Mehta, PhD and Professor of Cell & Molecular Pharmacology and SmartState Endowed Chair of Proteomic Biomarkers was recruited to MUSC in 2016 from Drexel University. Mehta’s research is currently funded by an NCI U01 and R01. Carsten Krieg, PhD is Assistant Professor of Microbiology & Immunology and recruited to MUSC in 2017 from the University of Zurich. His expertise in single cell cytometry by time of flight (CyTOF) was identified as a priority focal area for Cancer Immunology Program. Krieg is now building a technology platform within the HCC’s Flow Cytometry & Cell Sorting (FCCS) Shared Resource for high dimensional analysis using mass cytometry or conventional flow cytometers and high dimensional sorting for HCC investigators. In the next project period, the HCC requests $602,250 per year in developmental funds, 27% of the overall direct Cancer Center Support Grant request. These funds will be utilized in meeting the following specific aims: 1) Award pilot research funding to HCC investigators to promote team science, high risk/high reward ideas, and pre-clinical and clinical concepts; 2) Invest in new faculty start-up packages in support of the HCC six-year strategic plan; and 3) Support up to 20% effort for two early-stage clinical investigators annually who will be charged with developing innovative investigator-initiated trials.

行政基金：摘要 南卡罗来纳州医科大学（MUSC）的Hollings癌症中心（HCC）利用癌症免疫组织化学（ELISA）。 中心支持赠款（CCSG）发展基金，以推动其促进初级教育的战略计划 研究人员，团队科学，转化和临床研究，并支持战略教师招聘。 在本项目期间，共分配了633，635美元的CCSG发展资金用于试点 研究经费支持9个项目。包括CCSG基金在内，HCC共投资270万美元， 2013-2018年期间授予的试点研究基金，可直接与26美元的成功奖励挂钩 亿美元的校外多年赠款资金。这是CCSG投资的近10倍收益率 美元.此外，CCSG发展基金还为招聘三名新教师提供了支助 支持癌症生物学（CB）、发育性癌症 治疗学（DCT）和癌症免疫学（CI）计划。J. Alan Diehl，博士和生物化学教授 &分子生物学拥有脂质组学和病理生物学椅子的SmartState捐赠教授。Diehl 2014年，我从宾夕法尼亚大学被招入MUSC，担任基础教育副主任。 科学他的研究目前由NCI R 01和三个NCI P01资助。Anand Mehta博士， 细胞与分子药理学教授和蛋白质组学生物标志物的SmartState捐赠主席是 2016年从德雷克塞尔大学（Drexel University）招募到MUSC。梅塔的研究目前由NCI U 01资助， R01。Carsten Krieg博士是微生物学和免疫学助理教授，于2017年被MUSC招募 来自苏黎世大学。他在单细胞飞行时间细胞仪（CyTOF）方面的专业知识被认为是 癌症免疫学计划的优先重点领域。克里格现在正在建立一个技术平台， HCC的流式细胞术和细胞分选（FCCS）共享资源，用于使用质量进行高维分析 流式细胞仪或常规流式细胞仪和高维分选。未来 项目期间，HCC每年要求602，250美元的发展资金，占整个直接癌症的27%。 中心支持补助金申请。这些资金将用于实现以下具体目标： 向HCC研究者提供研究资金，以促进团队科学，高风险/高回报的想法，以及临床前 2）投资于新的教师启动包，以支持HCC六年战略计划; 和3）每年为两名早期临床研究者提供高达20%的支持，他们将负责 开发创新的药物启动试验。